


Biomedical HIV Prevention Efficacy Trials, 2014-2016 ***



*Trial end dates are estimates; due to the nature of clinical trials, the actual dates may change. For full trial details, see www.avac.org/pxrd.

**This table only includes efficacy evaluations of biomedical strategies in HIV-negative people. There are ongoing pilot and demonstration projects of oral PrEP, an open-label evaluation of 1% tenofovir gel in the community where CAPRISA 008 took place and numerous Phase I and II trials of other options.